The pharmaceutical formulation for inhibiting wound contraction of the present invention includes secretory leukocyte protease inhibitor as an active ingredient. The SLPI concentration in the pharmaceutical formulation is preferably 1-5000 ng/ml, and more preferably 1-100 ng/ml. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an external preparation including a base and the SLPI as an active ingredient. The pharmaceutical formulation for inhibiting wound contraction of the present invention may be prepared as an injection including the SLPI as an active ingredient. The external preparation may preferably include a preservative. The injection may preferably include a stabilizer (an antioxidant), a preservative and an analgesic agent.